BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22508521)

  • 1. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
    Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
    Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
    Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
    Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
    Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
    Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation.
    Yang T; Lan J; Huang Q; Chen X; Sun X; Liu X; Yang P; Jin T; Wang S; Mou X
    Cell Biochem Biophys; 2015 Jan; 71(1):291-7. PubMed ID: 25358405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release.
    Mohr A; Büneker C; Gough RP; Zwacka RM
    Oncogene; 2008 Jan; 27(6):763-74. PubMed ID: 17653087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
    Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
    Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
    Siegelin MD; Gaiser T; Siegelin Y
    Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.
    Aird KM; Allensworth JL; Batinic-Haberle I; Lyerly HK; Dewhirst MW; Devi GR
    Breast Cancer Res Treat; 2012 Feb; 132(1):109-19. PubMed ID: 21559822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
    Allensworth JL; Evans MK; Bertucci F; Aldrich AJ; Festa RA; Finetti P; Ueno NT; Safi R; McDonnell DP; Thiele DJ; Van Laere S; Devi GR
    Mol Oncol; 2015 Jun; 9(6):1155-68. PubMed ID: 25769405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
    Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
    Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
    Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation.
    Hu R; Yang Y; Liu Z; Jiang H; Zhu K; Li J; Xu W
    Tumour Biol; 2015 Feb; 36(2):769-77. PubMed ID: 25293521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells.
    Wehrkamp CJ; Gutwein AR; Natarajan SK; Phillippi MA; Mott JL
    PLoS One; 2014; 9(3):e90238. PubMed ID: 24603802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Effects of Mesenchymal Stem Cells and Various Agents on Apoptosis of Glioblastoma Cells.
    Tanrikulu B; Ziyal I; Bayri Y
    Turk Neurosurg; 2019; 29(1):26-32. PubMed ID: 29384188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.